Healthcare provider profile · identity verified

Mark Stuart Simmons, MD

Internal Medicine · TUSCON, AZ · NPI 1811092760

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	451	140
Lisinopril	Lisinopril	236	76
Amlodipine Besylate	Amlodipine Besylate	220	70
Levothyroxine Sodium	Levothyroxine Sodium	175	54
Meloxicam	Meloxicam	124	44
Metformin Hcl	Metformin Hcl	121	39
Simvastatin	Simvastatin	106	34
Pantoprazole Sodium	Pantoprazole Sodium	105	32
Losartan Potassium	Losartan Potassium	100	31
Rosuvastatin Calcium	Rosuvastatin Calcium	87	25
Tamsulosin Hcl	Tamsulosin Hcl	74	29
Metoprolol Succinate	Metoprolol Succinate	65	23
Trazodone Hcl	Trazodone Hcl	61	20
Allopurinol	Allopurinol	60	21
Prednisone	Prednisone	60	47
Zolpidem Tartrate	Zolpidem Tartrate	60	28
Finasteride	Finasteride	59	20
Carvedilol	Carvedilol	55	20
Furosemide	Furosemide	55	18
Omeprazole	Omeprazole	54	19
Gabapentin	Gabapentin	48	23
Venlafaxine Hcl Er	Venlafaxine Hcl	45	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	44	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	43	41
Hydrochlorothiazide	Hydrochlorothiazide	41	13
Azithromycin	Azithromycin	40	40
Pravastatin Sodium	Pravastatin Sodium	40	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	36	34
Eliquis	Apixaban	34	11
Clonazepam	Clonazepam	32	11
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	16
Sildenafil Citrate	Sildenafil Citrate	27	suppressed
Glimepiride	Glimepiride	26	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Synthroid	Levothyroxine Sodium	26	11
Albuterol Sulfate Hfa	Albuterol Sulfate	25	20
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	12
Ozempic	Semaglutide	24	suppressed
Chlorthalidone	Chlorthalidone	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Estradiol	Estradiol	20	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Cefuroxime	Cefuroxime Axetil	19	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Alendronate Sodium	Alendronate Sodium	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Famotidine	Famotidine	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Risperidone	Risperidone	15	suppressed
Valsartan	Valsartan	15	suppressed
Amoxicillin	Amoxicillin	14	14
Atenolol	Atenolol	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Mupirocin	Mupirocin	14	14
Lovastatin	Lovastatin	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Norethindrone	Norethindrone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error